AstraZeneca’s Seroquel XR Gets FDA Nod For Once-Daily Treatment Of Schizophrenia
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca plans to have the extended-release tablets on the market by late July, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
AstraZeneca Submits First Atypical Antipsychotic For Anxiety Indication
Supplemental NDA package for Seroquel XR includes data from four clinical studies, all of which met their primary endpoints.
AstraZeneca Submits First Atypical Antipsychotic For Anxiety Indication
Supplemental NDA package for Seroquel XR includes data from four clinical studies, all of which met their primary endpoints.
Early Adoption Of Invega Less “Robust” Than Anticipated, J&J Says
Atypical antipsychotic has a 4.4 percent share of the churn market for schizophrenia drugs since launch, firm reports.